NCT05720559View on ClinicalTrials.gov

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

March 1, 2023

Primary Completion Date

March 1, 2026

Study Completion Date

September 1, 2026

Conditions
Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
Interventions
DRUG

Oxaliplatin

Oxaliplatin via intravenous drip on d1 at a dose of 130mg/m2 × patient 's body surface area

DRUG

S1

Orally on d2-d15 at 20 mg three times daily

DRUG

Cetuximab

Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.

DRUG

Metronidazole

Metronidazole 0.4g/time, qd

DRUG

Vitamin A

Vitamin A 25,000 units/time, qd

DRUG

Folic acid

Folic acid 0.4 mg/time, qd

DRUG

Capecitabine

Capecitabine via orally on d2-d15 two times daily at a dose of 1000mg/m2 × patient 's body surface area.

All Listed Sponsors
lead

Liaoning Cancer Hospital & Institute

OTHER

NCT05720559 - Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection | Biotech Hunter | Biotech Hunter